Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Total Non-current Liabilities
All obligations due after more than one year.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 10.5% from a year ago
Total non-current liabilities stood at $45.47M at the end of Q1 FY2026, down 10.5% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Total non-current liabilities amounted to 13.6% of total assets at the end of Q1 FY2026, up 3.1 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -10.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 46.79M USD
- Year-over-year change
- -19.5%
- 4-year CAGR
- +229.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.79M | -19.5% |
| FY2024 | 2024-12-31 | 58.16M | -14.5% |
| FY2023 | 2023-12-31 | 68.04M | +288.1% |
| FY2022 | 2022-12-31 | 17.53M | +4326.8% |
| FY2021 | 2021-12-31 | 396K | — |
Total Non-current Liabilities vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's Mar 2026 total non-current liabilities of $45.47M is the 4th highest of the 11 companies compared; the peer median is $18.43M.
- Its year-over-year change of -10.5% is the 6th highest of 10, against a peer median of -4.1%.
- Total non-current liabilities amounts to 13.6% of total assets for TRDA, versus a peer median of 6.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.32B | +88832.8% | -8.4% | 1.5% | |
| Mar 2026 | $88.75M | -4.1% | -3.5% | 22.4% | |
| Mar 2026 | $82.75M | -22.3% | +11.9% | 74.8% | |
| Mar 2026 | $45.47M | -10.5% | +38.7% | 13.6% | |
| Mar 2026 | $28.2M | -30.1% | +2.2% | 12.9% | |
| Mar 2026 | $19.68M | -59.5% | -26.8% | 8.0% | |
| Mar 2026 | $17.18M | +3.5% | +2.1% | 4.0% | |
| Mar 2026 | $13.94M | +268.5% | -0.9% | 4.3% | |
| Mar 2026 | $10.59M | +6.5% | +445.3% | 32.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding TRDA) | $18.43M | -4.1% | +0.6% | 6.1% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291.06M | 45.16M | 67.6M | 101.21M | 90.39M |
| Short-term Investments | 0 | 143.56M | 284.37M | 318.79M | 205.3M |
| Net Receivables | 0 | 0 | 5.88M | 3.68M | 2.58M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 21.16M | 11.92M | 16.36M | 7.98M |
| Total Current Assets | 298.7M | 209.88M | 369.77M | 440.04M | 306.25M |
| Property, Plant & Equipment (Net) | 6.26M | 33.02M | 92.68M | 82.05M | 67.76M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 872K | 9.16M | 6.74M | 4.23M | 3.36M |
| Total Non-current Assets | 7.13M | 42.18M | 99.42M | 86.28M | 71.13M |
| Total Assets | 305.83M | 252.06M | 469.19M | 526.32M | 377.38M |
| Account Payables | 706K | 5.99M | 3.28M | 4.26M | 2.29M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 4.02M | 667K | 0 |
| Deferred Revenue | 0 | 0 | 132.26M | 13.65M | 342K |
| Other Current Liabilities | 4.56M | 5.49M | 7.66M | 8.43M | 9.22M |
| Total Current Liabilities | 6.72M | 21.97M | 158.8M | 39.48M | 24.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 7.72M | 6.51M | 0 |
| Other Non-current Liabilities | 396K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 396K | 17.53M | 68.04M | 58.16M | 46.79M |
| Total Liabilities | 7.12M | 39.5M | 226.83M | 97.64M | 71.25M |
| Common Stock | 3K | 3K | 3K | 4K | 4K |
| Retained Earnings | (93.67M) | (188.29M) | (194.97M) | (129.34M) | (273.09M) |
| Accumulated OCI | 0 | (2.06M) | 195K | (43K) | 652K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 298.72M | 212.55M | 242.36M | 428.68M | 306.13M |
| Total Debt | 0 | 25.94M | 68.23M | 59.21M | 50.93M |
| Net Debt | (291.06M) | (19.22M) | 628K | (42M) | (39.46M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.